Evidence map›Paper›PMID 38980071›Full record

ArticlemSphere2024

Efficacies of omadacycline + amikacin + imipenem and an all-oral regimen omadacycline + clofazimine + linezolid in a mouse model of

Elisa H Ignatius, Binayak Rimal, Chandra M Panthi, Daniel C Belz, Christopher K Lippincott, Daniel H Deck, Alisa W Serio, Gyanu Lamichhane

Abstract read
In one paragraph

Article in mSphere, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Article
  3. Journal of bacteriology · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. Toward better cures forClinical microbiology reviews · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Elisa H IgnatiusDivision of Infectious Diseases, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.ORCID 0000-0002-4760-0172
Binayak RimalDivision of Infectious Diseases, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Chandra M PanthiDivision of Infectious Diseases, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Daniel C BelzCenter for Nontuberculous Mycobacteria and Bronchiectasis, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Christopher K LippincottDivision of Infectious Diseases, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Daniel H DeckParatek Pharmaceuticals Inc., King of Prussia, Pennsylvania, USA.
Alisa W SerioParatek Pharmaceuticals Inc., King of Prussia, Pennsylvania, USA.ORCID 0000-0002-2351-6320
Gyanu LamichhaneDivision of Infectious Diseases, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.ORCID 0000-0002-2214-0114

Funding

Optimizing Anti-mycobacterial Therapy Using A Pharmacology-based ApproachK23AI159145 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Elisa Helen Ignatius · 2022 to 2026
$994k
NIAID NIH HHS K23 AI159145
6 · The paper itself

Abstract

Treatment outcomes for

Indexed as

AmikacinAnti-Bacterial AgentsClofazimineDisease Models, AnimalDrug Therapy, CombinationImipenemLinezolidMycobacterium abscessusMycobacterium Infections, NontuberculousTetracyclinesAdministration, OralAnimalsFemaleLungLung DiseasesMiceAmikacinAnti-Bacterial AgentsClofazimineImipenemLinezolidomadacyclineTetracyclinesamikacinclofazimineimipenemlinezolidM. abscessusomadacycline

Identifiers

PMID38980071
PMCPMC11288010

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.